| Dr Rebecca Crane-okada, PHD, RN, CNS, AOCN | |
|
214 Main St # 160, El Segundo, CA 90245-3803 | |
| (310) 640-1946 | |
| Not Available |
| Full Name | Dr Rebecca Crane-okada |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Oncology |
| Location | 214 Main St # 160, El Segundo, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063840197 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SX0200X | Clinical Nurse Specialist - Oncology | RN286815 (California) | Secondary |
| 364SX0200X | Clinical Nurse Specialist - Oncology | CNS619 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rebecca Crane-okada, PHD, RN, CNS, AOCN 214 Main St # 160, El Segundo, CA 90245-3803 Ph: (310) 640-1946 | Dr Rebecca Crane-okada, PHD, RN, CNS, AOCN 214 Main St # 160, El Segundo, CA 90245-3803 Ph: (310) 640-1946 |
News Archive
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.
A research study led by scientists from the Gregorio Marañón University Hospital in Madrid and the Network of Centres for Biomedical Research in Mental Health Networks (CIBERSAM) shows that adolescents experiencing a first outbreak of psychosis have lower levels of grey matter in their brains than healthy teenagers. Strangely, this change was seen in patients suffering from various psychoses, including bipolar illness and schizophrenia.
The immune system's killer cells deliver a tightly controlled, 3-phase knockout punch that kills intracellular parasites through a novel pathway that an international team led by researchers from the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital have named "microptosis."
› Verified 5 days ago